139 related articles for article (PubMed ID: 35101670)
1. Generation of human induced pluripotent stem cell lines from three patients affected by Catecholaminergic Polymorphic ventricular tachycardia (CPVT) carrying heterozygous mutations in RYR2 gene.
Cimarosti B; Canac R; De Waard S; Girardeau A; Gaignerie A; Derevier A; Forest V; Ronjat M; Le Marec H; Gourraud JB; Lemarchand P; De Waard M; Lamirault G; Gaborit N
Stem Cell Res; 2022 Apr; 60():102688. PubMed ID: 35101670
[TBL] [Abstract][Full Text] [Related]
2. Generation of two induced pluripotent stem cell lines from catecholaminergic polymorphic ventricular tachycardia patients carrying RYR2 mutations.
Kong X; Belbachir N; Zeng W; Yan CD; Navada S; Perez MV; Wu JC
Stem Cell Res; 2023 Jun; 69():103111. PubMed ID: 37210947
[TBL] [Abstract][Full Text] [Related]
3. Generation of two human induced pluripotent stem cell lines, LUMCi020-A and LUMCi021-A, from two patients with Catecholaminergic Polymorphic Ventricular Tachycardia carrying heterozygous mutations in the RYR2 gene.
Meraviglia V; Arendzen CH; Freund C; Atsma DE; Mummery CL; Bellin M
Stem Cell Res; 2020 May; 45():101764. PubMed ID: 32315959
[TBL] [Abstract][Full Text] [Related]
4. Generation of iPSC lines from CPVT patient carrying heterozygous mutation p.A2254V in the ryanodine receptor 2 gene.
Li W; Henze S; Luo X; Ulbricht Y; Richter A; Di Donato N; Wilde AAM; Guan K
Stem Cell Res; 2021 May; 53():102259. PubMed ID: 33640691
[TBL] [Abstract][Full Text] [Related]
5. Novel Calmodulin Variant p.E46K Associated With Severe Catecholaminergic Polymorphic Ventricular Tachycardia Produces Robust Arrhythmogenicity in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Gao J; Makiyama T; Yamamoto Y; Kobayashi T; Aoki H; Maurissen TL; Wuriyanghai Y; Kashiwa A; Imamura T; Aizawa T; Huang H; Kohjitani H; Nishikawa M; Chonabayashi K; Fukuyama M; Manabe H; Nakau K; Wada T; Kato K; Toyoda F; Yoshida Y; Makita N; Woltjen K; Ohno S; Kurebayashi N; Murayama T; Sakurai T; Horie M; Kimura T
Circ Arrhythm Electrophysiol; 2023 Mar; 16(3):e011387. PubMed ID: 36866681
[TBL] [Abstract][Full Text] [Related]
6. Generation of catecholaminergic polymorphic ventricular tachycardia patient-specific induced pluripotent stem cell line.
Colombani S; Bernardin AA; Vincenti M; Amédro P; Desprat R; Bernex F; Lemaitre JM; Pasquié JL; Lacampagne A; Meli AC
Stem Cell Res; 2022 Apr; 60():102727. PubMed ID: 35245853
[TBL] [Abstract][Full Text] [Related]
7. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.
Priori SG; Napolitano C; Memmi M; Colombi B; Drago F; Gasparini M; DeSimone L; Coltorti F; Bloise R; Keegan R; Cruz Filho FE; Vignati G; Benatar A; DeLogu A
Circulation; 2002 Jul; 106(1):69-74. PubMed ID: 12093772
[TBL] [Abstract][Full Text] [Related]
8. Using hiPSC-CMs to Examine Mechanisms of Catecholaminergic Polymorphic Ventricular Tachycardia.
Arslanova A; Shafaattalab S; Ye K; Asghari P; Lin L; Kim B; Roston TM; Hove-Madsen L; Van Petegem F; Sanatani S; Moore E; Lynn F; Søndergaard M; Luo Y; Chen SRW; Tibbits GF
Curr Protoc; 2021 Dec; 1(12):e320. PubMed ID: 34958715
[TBL] [Abstract][Full Text] [Related]
9. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.
Kujala K; Paavola J; Lahti A; Larsson K; Pekkanen-Mattila M; Viitasalo M; Lahtinen AM; Toivonen L; Kontula K; Swan H; Laine M; Silvennoinen O; Aalto-Setälä K
PLoS One; 2012; 7(9):e44660. PubMed ID: 22962621
[TBL] [Abstract][Full Text] [Related]
10. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.
Itzhaki I; Maizels L; Huber I; Gepstein A; Arbel G; Caspi O; Miller L; Belhassen B; Nof E; Glikson M; Gepstein L
J Am Coll Cardiol; 2012 Sep; 60(11):990-1000. PubMed ID: 22749309
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic mechanism of a catecholaminergic polymorphic ventricular tachycardia causing-mutation in cardiac calcium release channel RyR2.
Xiong J; Liu X; Gong Y; Zhang P; Qiang S; Zhao Q; Guo R; Qian Y; Wang L; Zhu L; Wang R; Hao Z; Wen H; Zhang J; Tang K; Zang WF; Yuchi Z; Chen H; Chen SRW; Zheng W; Wang SQ; Xu YW; Liu Z
J Mol Cell Cardiol; 2018 Apr; 117():26-35. PubMed ID: 29477366
[TBL] [Abstract][Full Text] [Related]
12. Bradycardia Is a Specific Phenotype of Catecholaminergic Polymorphic Ventricular Tachycardia Induced by RYR2 Mutations.
Miyata K; Ohno S; Itoh H; Horie M
Intern Med; 2018 Jul; 57(13):1813-1817. PubMed ID: 29434162
[TBL] [Abstract][Full Text] [Related]
13. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
[TBL] [Abstract][Full Text] [Related]
14. Mutation-specific differences in arrhythmias and drug responses in CPVT patients: simultaneous patch clamp and video imaging of iPSC derived cardiomyocytes.
Pölönen RP; Swan H; Aalto-Setälä K
Mol Biol Rep; 2020 Feb; 47(2):1067-1077. PubMed ID: 31786768
[TBL] [Abstract][Full Text] [Related]
15. Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia.
Sasaki K; Makiyama T; Yoshida Y; Wuriyanghai Y; Kamakura T; Nishiuchi S; Hayano M; Harita T; Yamamoto Y; Kohjitani H; Hirose S; Chen J; Kawamura M; Ohno S; Itoh H; Takeuchi A; Matsuoka S; Miura M; Sumitomo N; Horie M; Yamanaka S; Kimura T
PLoS One; 2016; 11(10):e0164795. PubMed ID: 27764147
[TBL] [Abstract][Full Text] [Related]
16. Slowed depolarization and irregular repolarization in catecholaminergic polymorphic ventricular tachycardia: a study from cellular Ca2+ transients and action potentials to clinical monophasic action potentials and electrocardiography.
Paavola J; Väänänen H; Larsson K; Penttinen K; Toivonen L; Kontula K; Laine M; Aalto-Setälä K; Swan H; Viitasalo M
Europace; 2016 Oct; 18(10):1599-1607. PubMed ID: 26705554
[TBL] [Abstract][Full Text] [Related]
17. Modeling polymorphic ventricular tachycardia at rest using patient-specific induced pluripotent stem cell-derived cardiomyocytes.
Sleiman Y; Souidi M; Kumar R; Yang E; Jaffré F; Zhou T; Bernardin A; Reiken S; Cazorla O; Kajava AV; Moreau A; Pasquié JL; Marks AR; Lerman BB; Chen S; Cheung JW; Evans T; Lacampagne A; Meli AC
EBioMedicine; 2020 Oct; 60():103024. PubMed ID: 32980690
[TBL] [Abstract][Full Text] [Related]
18. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.
Jung CB; Moretti A; Mederos y Schnitzler M; Iop L; Storch U; Bellin M; Dorn T; Ruppenthal S; Pfeiffer S; Goedel A; Dirschinger RJ; Seyfarth M; Lam JT; Sinnecker D; Gudermann T; Lipp P; Laugwitz KL
EMBO Mol Med; 2012 Mar; 4(3):180-91. PubMed ID: 22174035
[TBL] [Abstract][Full Text] [Related]
19. Calcium signaling consequences of RyR2 mutations associated with CPVT1 introduced via CRISPR/Cas9 gene editing in human-induced pluripotent stem cell-derived cardiomyocytes: Comparison of RyR2-R420Q, F2483I, and Q4201R.
Zhang XH; Wei H; Xia Y; Morad M
Heart Rhythm; 2021 Feb; 18(2):250-260. PubMed ID: 32931925
[TBL] [Abstract][Full Text] [Related]
20. Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations.
Novak A; Barad L; Lorber A; Gherghiceanu M; Reiter I; Eisen B; Eldor L; Itskovitz-Eldor J; Eldar M; Arad M; Binah O
J Cell Mol Med; 2015 Aug; 19(8):2006-18. PubMed ID: 26153920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
